NUTM2A-AS1 was found to regulate PD-L1 via the miR-376a/TET1/HIF-1A axis, and its overexpression enhances DDP resistance in GC cells, suggesting potential synergistic effects between chemotherapy and immunotherapy [79]. This evidence concerns the gene HIF1A and gastric cancer.